Table 3.
Clinical activity of avelumab
| (N=184) | |
|---|---|
| Complete response, n (%) | 1 (1) |
| Partial response, n (%) | 21 (11) |
| Stable disease, n (%) | 70 (38) |
| Progressive disease, n (%) | 69 (38) |
| Nonevaluable, n (%)* | 23 (13) |
| Objective response rate (95% CI), % | 12 (8–18) |
| Disease control rate, % | 50 |
| Median progression-free survival (95% CI), weeks | 11·6 (8·4–13·7) |
| Progression-free survival rate at 24 weeks (95% CI), % | 26 (20–33) |
| Progression-free survival rate at 48 weeks (95% CI), % | 18 (12–26) |
| Median overall survival (95% CI), months | 8·4 (7·3–10·6) |
| Overall survival rate at 12 months (95% CI), % | 36 (26–46) |
Response rates are based on confirmed responses.
*
Patients with missing and/or no assessable information included 19 patients without post-baseline tumour assessments (12 patients died within 6 weeks, one patient had an unevaluable post-baseline target lesion, four patients withdrew consent, and two patients discontinued due to disease progression) and four patients with stable disease who did not meet minimum duration requirement and in which there were no further tumour assessments during available follow-up.